CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022
March 15 2022 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
leveraging the power of the mitochondria and the peptides encoded
in its genome to develop potential breakthrough therapeutics
targeting chronic and age-related diseases, announced today
that the company will release its 2021 fourth quarter and full
year financial results after the market closes on Tuesday, March
29, 2022. Management will host a conference call and webcast at
5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on
the company’s business.
Details for the Conference Call:
Date: March 29, 2022 |
Time: 5:00 p.m. ET (2:00 p.m. PT) |
|
|
Conference Audio |
- |
Dial-in U.S. and Canada: (877) 451-6152 |
- |
Dial-in International: (201) 389-0879 |
- |
Conference ID No.: 13726040 |
|
|
Webcast |
- |
A
simultaneous webcast of the call will be accessible via the
Investors section of the CohBar website at www.cohbar.com. |
For individuals participating in the Investor Call or webcast,
please call or login to the conference audio approximately 10
minutes prior to its start.
An audio replay of the call will be available beginning at 8:00
p.m. Eastern Time on March 29, 2022, through 11:59 p.m. Eastern
Time on April 19, 2022. To access the recording please dial (844)
512-2921 in the U.S. and Canada, or (412) 317-6671 internationally,
and reference Conference ID# 13726040. The audio recording will
also be available at www.cohbar.com during the same period.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company
leveraging the power of the mitochondria and the peptides encoded
in its genome to develop potential breakthrough therapeutics
targeting chronic and age-related diseases with limited to no
treatment options. CohBar has assembled the leading position in
exploring the mitochondrial genome and its utility for the
development of novel therapeutics, including world-renowned
expertise in mitochondrial biology, a broad intellectual property
estate, key opinion leaders and disciplined drug discovery and
development processes. CohBar is utilizing its Mito+ platform to
identify and develop modified versions of natural peptides called
analogs to treat a variety of serious conditions, with a focus on
diseases involving inflammation and fibrosis.
For additional company information, please visit www.cohbar.com
and engage with us on LinkedIn.
Contacts:
Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Mar 2024 to Apr 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Apr 2023 to Apr 2024